Cytokinetics Capital Expenditures: 0.10M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYTK Capital Expenditures Rankings
| Overall | 68th percentile | 1388 of 4439 |
| Sector | 59th percentile | 209 of 510 in Healthcare |
| Industry | 44th percentile | 86 of 154 in Biotechnology |
CYTK Capital Expenditures Range, Past 5 Years
| Minimum | 0.13M | Mar 2004 |
| Maximum | 1.84M | Sep 2006 |
| Average |
About Capex
Capital expenditures are a line item from a company's statement of cash flows (click "Learn More" below for details).
Capex (short for capital expenditures) are incurred when a business spends money to purchase fixed assets or to add value to an existing fixed asset. In accounting, a capital expenditures are added to an asset account, thus increasing the value of the asset.
Examples of capital expenditures include the purchase of a new manufacturing plant, investment in server farms for tech companies, or other purchases of assets expected to help the company earn profits in the future.
Unlike other investments like research and development and marketing spending, capital expenditures are not immediately expensed. Rather, property, plant and equipment acquired using capital expenditures are usually expensed over time through the use of depreciation.
Learn More
You may also be interested in these CYTK related companies
CYTK News
Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Feb 02, 4:13PM Street Insider
Feb 02, 4:13PM Street Insider
Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Feb 02, 4:00PM Marketwire
Feb 02, 4:00PM Marketwire
Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012
Jan 26, 4:00PM Marketwire
Jan 26, 4:00PM Marketwire
Cytokinetics (CYTK) Reports Positive CK-2017357 Phase II, Part A Dat in ALS Patients
Nov 30, 7:32AM Street Insider
Nov 30, 7:32AM Street Insider
Cytokinetics to Present at Eighth Annual Lazard Capital Markets Healthcare Conference
Nov 08, 4:00PM Marketwire
Nov 08, 4:00PM Marketwire
Cytokinetics announces initiation of second cohort of Phase ll CK-2017357 trial
Nov 01, 7:38AM FlyOnTheWall
Nov 01, 7:38AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTK | 1.18 | -0.01 | -0.84% | 85.29M |
| CMLS | 3.79 | 0.00 | 0.00% | 199.01M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| AIG | 26.66 | -0.69 | -2.52% | 50.60B |
| INTC | 26.70 | -0.17 | -0.61% | 135.93B |
| ETFC | 9.21 | 0.02 | 0.22% | 2.63B |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
| ROCM | 8.08 | 0.12 | 1.51% | 99.06M |
| FITB | 13.35 | -0.17 | -1.29% | 12.27B |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
